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1. Introduction
Kidney and urinary tract cancers accounted for a total of 16936 cases and 6764 deaths in 2007
in Japan (Matsuda et al., 2012), which is roughly 2% of all cancers. Renal cell carcinoma (RCC)
is the most common type of kidney cancer, and is classified into three major subtypes, clear
cell RCC, papillary RCC and chromophobe RCC, representing 80, 10, and 5% of all RCCs, and
the majority of renal tumors are sporadic although 2-4% are hereditary (Hagenkord et al., 2011).
A number of genes have been studied in association with renal tumors, including those
involved in tumorigenesis, and the progression and outcome of the cancer, by means of
mutational searches, gene expression profiling, proteomics/metabolomics and pathological/
clinical studies. The genes can be classified into several categories, such as familial, sporadic,
epigenetic and quantitative, depending on the timing of their expression, and the factors
affecting their effects, such as microRNA (miRNA) and metabolites have emerged. Since
tumorigenesis is believed to be initiated with genetic/epigenetic modulations of at least several
genes, but not a single gene alone, the balance among these cancer-related genes is considered
to be more important than the contribution of a dramatic change caused by a single gene. Thus,
an extensive and competitive search for oncogenes and tumor suppressor genes based on the
search for their mutations was immediately accompanied by the search for interacting
proteins/factors at the mutation sites. This indicates that lineages of gene functions, or signaling
pathways, are important to understanding tumorigenesis, as well as the progression and
outcome of the cancer. Although such pathways are not fully understood, it is important to
summarize the latest knowledge of genes and their functions in terms of the coordinated
functions of genes to achieve a basic understanding of cancer and to use the information
obtained for diagnostics/therapeutics.
Here, we summarize and discuss the genes associated with renal tumors (Section 2) and then
show one of them, Kank1, from gene-function networks or signaling pathways (Section 3). We
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also discuss a methodology for collecting information on multiple gene functions with a simple
pathological system (Section 4).
2. Genes associated with renal tumors
While kidney cancer ranked 9th in 2002 in the European Union and the United States
(Baldewijns et al., 2008), its mortality rate was not high in Japan (12th in 2002 and 2007: Matsuda
et al., 2012). Although this difference could be attributable to risk factors such as smoking,
hypertension and long-term dialysis, there might be a contribution of genes associated with
the cancer. In spite that RCC shows a poor survival rate (less than 19%) for patients with
metastasis, molecular pathological tests, such as those dividing good and poor prognosis
groups, have not been established (Stewart et al., 2011). A lack of such effective tests may be
one of the reasons why the mortality rate in Japan has been gradually increasing from 1.8%
(2002) to 2.0% (2007).
A large majority of RCC cases are sporadic and only 2-4% are hereditary. There are cas‐
es  where  gene expression profiling cannot  distinguish between them (Beroukhim et  al.,
2009),  suggesting common genetic factors between them. Several genes are known to be
associated  with  RCC,  such  as  VHL,  TSC1  and  TSC2,  which  play  different  roles  in  the
mechanism of  cancer  and  so  have  different  advantages  in  diagnostics/therapeutics.  The
information  about  genes  can  be  categorized  by  the  levels  of  genomics,  transcriptomics,
proteomics  and others  including metabolomics,  and used to  understand the mechanism
of cancer, to support diagnostic or therapeutic processes. In this section, we focus on the
roles and merits of these genes.
2.1. Genes associated with tumorigenesis
Since a majority of sporadic cancers originate from a recessive mutation that causes a loss of
function of a particular type of gene, loss of heterozygosity (LOH) is an important step in the
disabling of a functional gene (or a wild-type allele) to give a mutated and cancer phenotype.
Such genes are termed tumor suppressor genes, and so far, more than 100 have been reported
(Fearon, 2002; Polinsky, 2007). Among them, twenty well-characterized genes showed both
familial and sporadic phenotypes (Sherr, 2004). Since a cancer phenotype can be revealed by
morphological changes, growth stimulation, gaining immortality and/or others, there are quite
a few functions associated with tumor suppressor genes. Thus, it is easier to examine tumori‐
genesis in association with genomic status, mutations and/or epigenetic modifications, by
analyzing the loci specific to RCC.
2.1.1. VHL gene
The gene best known to be associated with RCC is the von Hippel-Lindau (VHL) gene, whose
inactivation accounts for nearly 100% of hereditary cases and sporadic clear cell RCC cases
(Baldewijns et al., 2008). This gene was found by positional cloning from the locus associated
with the VHL disease, a familial syndrome accompanying cancer in the eye, brain, spinal cord,
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kidney, pancreas and adrenal glands. The VHL gene encodes the 30-kDa protein VHL, 213
amino acid residues long, and is implicated in the regulation of hypoxia-inducible factors
(HIFs) (Maher et al., 2011). The VHL protein forms a complex with elongin B, elongin C and
cullin-2, and the complex has ubiquitin ligase E3 activity and is involved in the ubiquitination
and degradation of HIFα, the α subunits of transcription factors HIF-1 and HIF-2, which form
a dimer with HIFβ and regulate the transcription of hypoxia-inducible genes such as those for
VEGF (vascular endothelial growth factor), PDGF (platelet derived growth factor) and TGFα
(transforming growth factor α) (Kondo and Kaelin, 2001; Kaelin, 2009; Fig. 1). However, the
cancer found in VHL disease is sporadic and the lifetime risk of RCC in VHL disease patients
is about 70% (Maher et al., 2011). So, it is reasonable to assume that additional genes are
involved in RCC and the mutations in VHL are not the definitive cause of RCC, which is one
of the reasons to explore new genes and genetic loci (see below). Meanwhile, the status of the
VHL gene is important for the treatment of VHL disease and kidney cancer patients. HIF-
responsive gene products, such as VEGF and PDGF, activate the angiogenesis of tumors and
therefore are good therapeutic targets. Inhibitors of VEGF and PDGF, sunitinib and sorafenib,
have been approved by the US Food and Drug Administration (Kaelin, 2009).
Figure 1. Summary of signal transduction pathways associated with RCC.




The MET protooncogene was found in hereditary papillary RCC without mutations in the VHL
gene (Schmidt et al., 1997). MET encodes a membrane receptor (MET) for hepatocyte growth
factor (HGF). MET has tyrosine kinase activity, and HGF activates this kinase activity and
initiates signaling for mitogenesis and migration (Fig. 1). While aberrantly active MET triggers
tumor growth, angiogenesis and metastasis, such cases are relatively rare (~5%) among
sporadic papillary RCC, suggesting other genes to play a major role in the tumorigenesis
(Baldewijns et al., 2008).
2.1.3. TSC1/TSC2 genes
Two tumor suppressor genes, TSC1 and TSC2, were found in a study of tuberous sclerosis
complex (TSC), which is known to develop into various types of RCCs, including clear cell
RCC, papillary RCC and chromophobe RCC (Borkowska et al., 2011). The TSC1 and TSC2
proteins form a heterodimer and inhibit the mammalian target of rapamycin (mTOR; a key
signaling mediator for cell growth), by inactivating a small GTPase Rheb (an activator of
mTOR) as a GTPase-activating protein (GAP) (Linehan et al., 2010; (Fig. 1). However, muta‐
tions are not frequently found in sporadic RCC (Parry et al., 2001) and therefore its role is not
completely clear yet.
2.1.4. PBRM1 gene
Several genes, UTX (or KDM6A), JARID1C (or KDM5C) and SETD2, were found in close
association with clear cell RCC by a recent technology of the next-generation sequencing
(Dalgliesh et al., 2010). As these genes are related with the methylation status of lysine residues
of hitone H3, further mutation studies were conducted to identify a SWI/SNF chromatin
remodeling complex gene, PBRM1, to be frequently (over 40%) mutated in clear cell RCC
(Varela et al., 2011). PBRM1 is mapped to chromosome 3p21 and encodes the BAF180 protein,
a chromatin targeting subunit of a SWI/SNF chromatin remodeling complex, which regulates
replication, DNA repair and cell proliferation/differentiation. Knock-down of this gene
enhanced colony formation and migration of cancer cells, suggesting this gene to be a tumor
suppressor gene. Further studies are needed to reveal a mechanism of cancer involving PBRM1
and to find its clinical application.
2.1.5. Genes related to hereditary renal cancer syndromes
Approximately 2-4% of RCC cases are hereditary and some genes have been identified as the
genes responsible for hereditary renal cancer (HRC) syndromes (Verine et al., 2010). Apart
from the genes already mentioned above (VHL, MET, TSC1 and TSC2), several more genes
have been described in association with HRC syndromes, including FH and FLCN genes. FH
is the gene responsible for a HRC syndrome, hereditary leiomyomatosis and renal cell cancer
(HLRCC), in which affected individuals often develop cutaneous and uterine leiomyoma and
an aggressive form of papillary RCC (Linehan et al., 2004). The FH gene encodes an enzyme
(FH) catalyzing the conversion of fumarate to malate in the tricarboxylic acid (Krebs) cycle.
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From the analysis of their mutations, this gene is considered as a tumor suppressor gene
(Sudarshan et al., 2007). Although the mechanism that leads FH alterations to cancer is not
clearly understood, there is a link between fumarate dysregulation and impaired HIF hydrox‐
ylation (Isaacs et al., 2005).
FLCN, on the other hand, is the gene responsible for Birt-Hogg-Dubé (BHD) syndrome, which
is a rare autosomal dominant disease including kidney tumors, predominantly chromophobe
RCC. Mutations in this gene were found in approximately 80% of BHD kindreds and loss of
expression of this gene were frequently found in kidney tumors from BHD patients, suggesting
this gene to be a tumor suppressor gene (Baldewijns et al., 2008).
2.1.6. Other genes
Several genes were recently implicated in association with RCC, including BAP1, SETD2 and
NF2, by means of advanced technologies such as the next-generation sequencing, a microarray-
based analysis and a mouse transgene analysis. BAP1 plays a role of a tumor suppressor and
encodes a nuclear deubiquitinase, which is inactivated in 15% of clear cell RCC cases (Peña-
Llopis et al., 2012). Mutations in BAP1 anticorrelates with those in another tumor suppressor
gene, PBRM1, and these mutations comprise a subtype of clear cell RCC (70% of all clear cell
RCC cases). The BAP1 protein may work with host cell factor-1 (HCF-1), a scaffold protein, to
regulate transcription factors and suppress cell proliferation.
SETD2 was found by the analysis of accumulated transcripts containing premature termina‐
tion codons and encodes a histone methyltransferase, which is responsible for trimethylation
of the lysine residue at position 36 of histone H3 and may play a role in suppressing tumor
development (Duns et al., 2012).
NF2  was identified as a tumor suppressor gene by the analysis of knock-out mice (Mor‐
ris and McClatchey, 2009). The mice developed kidney tumors in 6-10 months with char‐
acteristics of hyperactive epidermal growth factor receptor (EGFR) signaling. Merlin,  the
NF2  gene product,  was implicated in suppressing tumorigenesis by inhibiting hyperacti‐
vated EGFR signaling.
2.2. Genes implicated in diagnostic markers and therapeutic targets
The recurrence of RCC is 20 to 40%, depending on the stage and grade of tumor (Chin et al.,
2006). So, it is important to understand the genes (and their products) associated with pro‐
gression/metastasis to predict the outcome of cancer. The classification of RCC subtypes is
apparently not possible by a single marker, but could be done using combinations of markers
such as vimentin, epithelial cell adhesion molecule (EpCAM), glutathione S-transferase α
(GSTα), carbonic anhydrase II (CA II), cytokeratin 7 (CK7) and cluster of differentiation 10
(CD10) (Stewart et al., 2011).
Important  prognostic  markers  for  RCC  represent  specific  cellular  signaling  pathways,
such  as  the  VHL  and  mTOR  pathways.  The  VHL  pathway  gives  several  well-studied
markers, such as VHL, HIFs, VEGF and carbonic anhydrase 9 (CAIX), although their ap‐
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plicability is sometimes questionable (Stewart et al.,  2011). HIF-responsive gene products
are  potential  markers  representing angiogenesis  (VEGF,  PDGF,  SDF,  CXCR4,  TGFβ and
CTGF), glucose uptake and metabolism (HK2 and PDK4), pH control (CAIX and CAXII),
invasion/metastasis  (MMP1,  SDF,  CXCR4  and  c-Met),  and  proliferation  and  survival
(TGFα) (Smaldone and Maranchie, 2009).
Another pathway for potential makers is the mTOR pathway (Fig. 1). The main cascade of this
pathway is PI3K/AKT/mTOR, which mediates signals by activating phosphoinositide 3-kinase
(PI3K) through kinases such as receptor tyrosine kinases to generate phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), which further activates AKT via phosphorylation and phospho-
AKT activates mTOR complex 1 (mTORC1) through inhibition of the TSC1/TSC2 complex
(Allory et al., 2011). Then, mTORC1 phosphorylates proteins such as P70-S6 kinase and
activates protein synthesis and cell proliferation. Importantly, HIF-1α expression is dependent
on mTORC1 signaling (Toschi et al., 2008). Potential markers in this pathway include P70-S6
kinase, PTEN (a phosphatase that decreases PIP3) and phospho-AKT.
2.3. Mutation sites and LOH loci
A comprehensive analysis of RCC genomes has been done through genomic (Hatano et al.,
2001; Cifola et al., 2008), transcriptomic (Takahashi et al., 2001; Takahashi et al., 2003; Cifola et
al., 2008) and proteomic/metabolic (Perroud et al., 2006; Raimondo et al., 2012) approaches.
We used a genome-subtraction technique, or the in-gel competitive reassociation method
(Kiyama et al., 1995; Rodley et al., 2003), for cloning the sites of LOH that occurred in a RCC
genome by subtracting normal DNA from cancer DNA of the same patient (Hatano et al.,
2001). The minimum size of LOH (caused by hemizygous deletions) detected by this method
was roughly 50 kb. This resolution was made possible by MseI, which recognizes TTAA, a
sequence appearing frequently in human genomic DNA, and completely digests genomic
DNA to sizes mostly below 1 kb. Such a high resolution has not been used even in recent
genome-wide association studies (see Jacobs et al., 2012, for example). A total of 187 clones
were mapped on the chromosomes and a total of 44 candidate regions, where at least two
clones were mapped within 5 Mb, were selected and analyzed for mapping the sites of LOH
in 61 cancer cases (Table 1). Among them, we found interesting LOH sites at 5q32-q34, 6q21-
q22, 8p12 and 9p24, whose frequencies are relatively high among RCC and whose lengths are
less than ~10 Mb (Hatano et al., 2001; Sarkar et al., 2002; Fig. 2). A tumor suppressor gene,
Kank1, was found at 9p24 after extensive analysis of the LOH site by examining the loss of
function upon its mutation; the loss of expression of the gene at mRNA and protein levels in
RCC, and the loss of suppression of tumor growth in renal tumor cells (Sarkar et al., 2002).
2.4. Chromosomal abberations in RCC
Chromosomal abberations are often observed in RCC (Ross et al., 2012). Deletions of chromo‐
some 3p, where the VHL gene resides, are found in most sporadic and familial clear cell RCCs.
Distinctive abnormalities were reported for papillary RCC, where, in contrast to clear cell RCC,
most of the tumors are characterized by trisomy of chromosomes 7 and 17 along with loss of
Y, while the 3p arm is intact. In Xp11.2 RCC, the gene fusion was observed between the TFE3
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gene on the X chromosome and either of ASPL (17q25), PRCC (1q21), PSF (1q34), NonO (Xq12)
and CLTC (17q23) (Kuroda et al., 2012). All of the gene fusions result in overexpression of the
TFE3 protein, a transcription factor. Among them, the translocation of t(X;17)(p11.2q25), which
fuses the ASPL and TFE3 genes, is most frequently observed. Meanwhile, there are some
unclassified cases, such as those where trisomy 7/17 in areas typical of papillary RCC and both
trisomy 7/17 and 3p loss in areas with clear cell RCC were observed (Ross et al., 2012).
2.5. Exploration of new genetic markers
Even though a number of genetic markers have been reported, they are not currently used for
the diagnosis of RCC. As discussed in Section 1, this is because understanding a single gene
or a few genes is not enough for a diagnosis of sufficient reliability. For diagnosing more
complex and more specific states of diseases or disease phenotypes, groups of markers that
are able to more accurately distinguish the phenotypes are needed. Such markers should be
derived from the direct process of the disease and therefore would represent the signal
transduction that occurs within the cell. There are several new technologies which might open
the door to a more comprehensive understanding of RCC especially at the level of cellular
signaling: array-based genome-wide association studies, microRNA (miRNA) studies and
next-generation sequencing-based expression profiling.
Figure 2. Significant LOH regions in RCC. LOH regions of less than ~10 Mb were identified as the minimum overlap‐
ping regions of LOH by subtraction cloning of mutated regions followed by the quantitative allelic analysis of over 60
RCC cases using microsatellite markers (see Hatano et al., 2001; Sarkar et al., 2002).































Table 1. Summary of LOH at significant locations among 44 sites. For details, see Hatano et al. (2001) and Sarkar et al.
(2002). Only the loci in which more than 10 % of RCC patients had LOH are shown. The LOH analysis is applicable to
only female patients for the cluster at Xq26-q28. There were a total of 44 clusters containing more than two of 187
clones analyzed within 5 Mb. The locations of the clusters other than those shown above are as follows: 1p31.1,
1p13.3-p22.3, 1p13.3-q12, 1q12-p21.1, 2p21-p22, 2p12-q11.2, 4p14, 4p13.3-p21.1, 4q22, 4q32, 10p14-p15.1,
10p12.1-p12.2, 12q13.3-q15, 13q13-q14.1, 13q14.2-q14.3, 16q12.1-q12.2, and 20p11.2-p12.
Recent advances in high-resolution genomic arrays have enabled us to analyze 1,000 or more
disease cases efficiently, and thus to give statistically significant loci associated with the
diseases. Such an approach was applied to the study of RCC. A genome-wide association study
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based on more than 5,000 RCC cases revealed two loci, 2p21 and 11q13.3, to be associated with
RCC susceptibility (Purdue et al., 2011). Although the authors claimed these sites to be
previously unidentified, both of the loci were actually identified in 2001 (Hatano et al., 2001;
Table 1). While the association is statistically significant, the frequencies among RCC cases are
not very high (less than 20%), and therefore, it is doubtful that these sites alone can be used
for diagnosis. The candidate genes in these loci which contribute to the association are EPAS1
encoding hypoxia-inducible factor-2α (HIF2α) and SCARB1 encoding a scavenger receptor.
While HIF2α was known to be associated with RCC though it has not yet been used clinically,
SCARB1 is new and its association with RCC may indicate a new signaling pathway. The array-
based genome-wide association technique was also applied to the study of copy-number
variations (Krill-Burger et al., 2012).
The study of miRNA is rapidly providing as new information about disease phenotypes.
MiRNA, a group of short non-coding RNA with lengths of 19-22 nucleotides, differs from
mRNA in that it has a role in gene function, and, while information about mutations is
important for mRNA, quantity is mostly emphasized for miRNA. So, while there are cases
where mRNA bearing a mutation without a change in its quantity contributes to a disease
phenotype, there would be few such cases for miRNA. Naturally, the linkage of a disease to a
genomic location reveals in most cases a mutation in a gene. This may indicate that miRNA
contributes to quantitative change as a group as a result of changes in transcriptional efficiency
caused by alterations to the transcriptional machinery or genomic location/status, or by
epigenetic modifications. In contrast to mRNA, however, the quantity of miRNA can be
controlled rapidly and specifically, and thus, miRNA could be more advantageous for the
rapid control of the amount of specific proteins, which is important in signal transduction.
Such cases were reported for TGFβ, WNT, Notch and EGF signaling in association with
homeostasis, cancer, metastasis, fibrosis and stem cell biology (Inui et al., 2010), and VHL-
signaling and VEGF-signaling in association with RCC (Fendler et al., 2011). Several miRNAs
were reported to be induced or repressed by VHL-induced hypoxia in RCC and regulate the
PI3K/AKT/mTOR pathway and Wnt signaling/β-catenin pathway to control cell proliferation,
tumorigenesis and other cellular functions (Redova et al., 2011).
Next-generation sequencing technology was applied to genome-wide expression profiling of
miRNA related to clear cell RCC (Osanto et al., 2012). By analyzing 22 RCCs, 100 miRNA
differentially expressed between clear cell RCC and matched normal tissues were found. While
the biological relevance of these novel miRNAs is unknown, they may be potential diagnostic
markers or targets for therapeutics.
3. Kank family genes and renal tumors
3.1. Structure of Kank-family genes
The human Kank1 gene was found as a candidate tumor suppressor gene for renal tumors at
9p24, and encodes a protein containing ankyrin-repeats at the C-terminus and coiled-coil
motifs near the N-terminus (Sakar et al., 2002). Based on domain and phylogenetic analyses,
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Kank2, Kank3 and Kank4 were found to form a family with Kank1 (Zhu et al., 2008). Five repeats
of the ankyrin-repeat motif comprise the basic structure of all Kank proteins (Fig. 3A). In
addition, each Kank protein contains different combinations of four types of coiled-coil motifs.
They also have a conserved region close to the N-terminus, named the KN-motif (Zhu et al.,
2008; Fig. 3A), which contains a leucine-rich region and an arginine-rich region.
Figure 3. (A) Schematic structure of human Kank family proteins. Black boxes indicate the Kank N-terminal (KN) motif.
Gray boxes indicate coiled-coil motifs. White boxes indicate the ankyrin-repeat (ANK) motifs. (B) A hypothetical model
of Kank1 functions. Kank1 is transported to areas of membrane ruffling, such as lamellipodia, through association
with Kif21a. Kank1 regulates RhoA and Rac1 activities through interaction with 14-3-3 in PI3K/Akt signaling and
IRSp53 in Rac1 signaling, respectively. These interactions negatively regulate the formation of actin stress fibers and
lamellipodia, and finally decrease cell migration. Kank1 and BIG1 may exist in a multimolecular complex that affects
Golgi/MTOC orientation and regulates cell polarity during directed migration. Kank1 may inhibit Rho activation by
binding to Rho-regulating proteins, like Daam1, which may result in negative regulation of cytokinesis.
Yeast-two hybrid or mass-spectrometrical studies have shown that Kank1 can directly bind to
several proteins, such as 14-3-3 proteins, insulin receptor substrate (IRS) p53, Kif21a and
Disheveled-associated activator of morphogenesis 1 (Daam1). Kank1 binds to IRSp53 and
Daam1 at its coiled-coil domain (Kakinuma et al., 2011). In addition, there is a 14-3-3-binding
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motif, serine at position 167, located between the first and second coiled-coil motifs. Kif21a is
a unique protein found to interact with the ankyrin-repeat domain of Kank1 (Kakinuma et al.,
2008 & 2009; Roy et al., 2009; Suzuki et al., unpublished data). Although the function of the
KN-motif is not clear, it contains several potential motifs for a nuclear localization signal (NLS)
and nuclear export signal (NES). These signals may contribute to nucleo-cytoplasmic shuttling
of Kank1, and further affect the subcellular distribution of β-catenin (Wang et al., 2006; Previdi
et al., 2010).
3.2. Functions of Kank-family genes
Some studies have demonstrated that Kank-family genes are related to various cell func‐
tions. VAB-19, an ortholog of the Kank1 protein in C. elegans, was reported to occur with
components  of  an  epidermal  attachment  structure.  It  plays  an  antagonistic  role  in  the
regulation  of  actin  cytoskeleton and halts  basement  membrane opening associated with
cell invasion and tissue remodeling (Ding et al.,  2003; Ihara et al.,  2011). The deletion of
Kank1  is associated with parent-of-origin-dependent inheritance of familial cerebral palsy
(Lerer et al.,  2005). There have also been reports that Kank1  was fused with the gene for
platelet-derived growth factor receptor β (PDGFRβ) and that the fusion protein was a vi‐
tal regulator of hematopoietic cell proliferation (Medves et al.,  2010 & 2011). Meanwhile,
Kank1  expression  was  down-regulated  in  patients  with  polycythemia  vera,  suggesting
this gene to be related to myeloproliferative disorders (Kralovics et al., 2005). Some stud‐
ies have described about the functions of other Kank-family members. Kank2, found as a
novel podocyte-associated protein, may contribute to the regulation of actin dynamics in
podocyte  foot  processes  in  the  renal  filter  physiology and diseases  (Xu et  al.,  2011).  In
addition, NBP, an ortholog of Kank3 in zebrafish, interacts with Numb, an adaptor pro‐
tein  implicated  in  various  basic  cellular  processes,  through  the  PTB  domain,  which  is
well conserved among vertebrate Kank  genes. In embryogenesis, NBP accumulates at the
cell  periphery  during gastrulation  and,  later  in  the  development,  is  concentrated at  the
basal  poles  of  differentiated  cells.  These  findings  suggest  a  role  for  NBP  in  regulating
cell adhesion and tissue integrity (Boggetti et al., 2012).
Kank1 may contribute to several regulatory activities, such as regulation of the actin cytoske‐
leton, cell migration and the cell cycle through interactions with the proteins described above
(Sakar et al., 2002; Kakinuma et al., 2008 & 2009; Roy et al., 2009; Suzuki et al., unpublished
data; summarized in Fig. 3B). Kank1 regulates the Rac1-dependent formation of lamellipodia
and the activity of RhoA, resulting in the inhibition of cell migration. This function is mediated
through two binding partners of Kank1, 14-3-3 and IRSp53. Kank1 binds to the Akt-phos‐
phrylation motif of 14-3-3θ, 14-3-3γ, 14-3-3η and 14-3-3ε. Interaction between these two
proteins is enhanced by growth factors such as insulin and epidermal growth factor (EGF)
(Kakinuma et al., 2008). This interaction regulates the activation of RhoA through the
PI3K/Akt signaling pathway. When a 14-3-3 binding motif is phosphorylated by Akt, 14-3-3
is separated from an activation complex for RhoA, and binds to Kank1 resulting in the
inhibition of RhoA activities, and thereby decreases the formation of actin stress fibers and
inhibition of cell migration (Kakinuma et al., 2008). The coiled-coil domain of IRSp53, which
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is the site for the interaction with active Rac1, binds to Kank1. Endogenous Kank1 and IRSp53
are co-localized at the site of membrane protrusions such as lamellipodia, which are needed
for cell migration. Overexpression of Kank1 inhibits the formation of lamellipodia induced by
active Rac1 in NIH3T3 cells, and knockdown of Kank1 enhances the formation. Therefore,
Kank1 negatively regulates membrane protrusions at the leading edge of cells, by inhibiting
the association between active Rac1 and IRSp53 (Roy et al., 2009). Taken together, Kank1
regulates cell migration through inhibition of IRSp53 in Rac1 signaling and inactivation of
RhoA activity through PI3K/Akt signaling (Fig. 3B). As the Kank1 locus shows loss of heter‐
ozygosity in RCC and the expression of the Kank1 gene is suppressed in RCC, Kank1 may
contribute to the malignant transformation of cells such as metastasis.
Kank1 regulates cell migration by inhibiting Rac1 signaling and RhoA activity as descri‐
bed above. To fulfill this function, Kank1 needs to be located at the leading edge of cells
and affect  the neighboring membrane.  Because Kank1 has no membrane-targeting motif
or membrane protein to associate with,  some proteins may help transport  Kank1 to the
site of membrane ruffling. Kank1 interacts with the third and fourth coiled-coil domains
of KIF21a, a member of the Kif4-class superfamily of kinesin motors that acts as a plus-
end kinesin  motor  (Marszalek  et  al.,  1999;  Kakinuma et  al.,  2009),  at  its  ankyrin-repeat
domain.  Overexpression  of  Kif21a  or  one  of  the  Kif21a  mutants  (R954W)  enhances  the
translocation of Kank1 to the membrane. In contrast, knockdown of Kif21a decreases the
amount  of  Kank1  at  the  membrane  (Yamada  et  al.,  2005;  Kakinuma  et  al.,  2009).  Al‐
though the mechanisms involved need further study, translocation of Kank1 mediated by
Kif21a  may  affect  cell  migration  (Fig.  3B).  Kank1  is  also  functionally  associated  with  a
protein, brefeldin A-inhibited guanine nucleotide-exchange 1 (BIG1), a binding partner of
Kif21a. Although there is no direct interaction between these two proteins, they may ex‐
ist  in a multimolecular complex that maintains the orientation of the Golgi/microtubule-
organizing  center  (MTOC)  and  regulates  cell  polarity  during  directed  migration.
Furthermore, a protein complex containing BIG1, Kif21a and Kank1 may contribute to di‐
rected transport along microtubules (Li et al., 2011).
Overexpression  of  Kank1  suppresses  the  cell  cycle  and cell  growth  (Sakar  et  al.,  2002).
We  observed  that  the  overexpression  of  Kank1  blocked  cytokinesis  and  generated  bi‐
nucleated  cells.  We  also  found  co-localization  of  endogenous  Kank1  with  Rho,  a  key
molecule required in cytokinesis for regulating the constriction of the contractile ring, at
the contractile ring during cytokinesis of NIH3T3 cells (Kamijo et al., 2006; Li et al., 2010;
Kakinuma et al., 2011; Suzuki et al., unpublished data). The coiled-coil domain of Kank1
binds to  another  protein,  Daam1 (Suzuki  et  al.,  unpublished data).  Daam1 belongs to a
novel  protein  family  containing  formin  homology  domains  and  has  been  implicated  in
the  regulation  of  cell  polarity  associated  with  the  Wnt/Frizzled/Rho  signaling  pathway
(Jantsch-Plunger  V et  al.,  2000;  Kosako H et  al.,  2000).  Although the  mechanism is  still
not  clear,  Kank1  may  block  cytokinesis  by  regulating  Rho  activity  through the  interac‐
tion  with  Daam1 (Fig.  3B).  Therefore,  it  may reveal  a  new mechanism of  regulation  of
cytokinesis and tumor suppression.
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3.3. Kank-family genes and renal tumors
The Kank1 gene was found at 9p24 by a comprehensive analysis of human chromosomes for
loss of heterozygosity (LOH) in RCC (Sakar et al., 2002). Kank1 family proteins localize at the
area of cytoplasma in renal tubular cells and glandular cells of some digestive and endocrine
organs (Roy et al., 2005). Kank family genes show different expression patterns at the mRNA
and protein levels in normal and tumor kidney tissues and some kidney tumor cell lines (Zhu
et al., 2008; Wang et al., 2005). Loss of expression of Kank1 in RCC was confirmed by Western
blotting, RT-PCR and immunohistochemical analyses (Sakar et al., 2002, Roy et al., 2005). In
addition, immunostaining in RCC showed decreased expression of Kank1 in high grade
tumors (Zhu et al., 2011). Therefore, the Kank family genes may be related to renal carcinoma,
and function as tumor suppressors.
A  growth  inhibitory  effect  of  Kank1  has  been  reported.  Overexpression  of  Kank1  in
HEK293 cells  resulted in cell  cycle  arrest  at  G0/G1.  On the other  hand,  growth suppres‐
sion of tumor cells  was caused by Kank1  gene expression using nude mice abdominally
injected  with  HEK293  cells  stably  expressing  Kank1  (Sakar  et  al.,  2002).  These  findings
demonstrated that Kank1 can regulate the growth of  cells  and can also regulate the ab‐
normal growth of cancer cells. Kank1 may exert its growth inhibitory effect by regulating
Rho activity mediated via its association with Daam1, resulting in abnormal nuclear divi‐
sion,  and thus blocking the cytokinesis  of  cancer cells  (Suzuki et  al.,  unpublished data).
According to recent studies,  Kank1 can negatively regulate the formation of  actin stress
fibers and cell migration (Kakinuma et al., 2008; Roy et al., 2009). When cells need to con‐
trol migration, Kank1 could be transferred to the leading edge of the moving cells’ mem‐
branes,  mediated  by  Kif21a,  and  co-localized  with  IRSp53.  Kank1  may  bind  to  IRSp53
competing  with  active  Rac1,  and  thus  inhibits  integrin-induced  cell  spreading  and  the
formation of lamellipodia. Simultaneously, Kank1 may inactivate RhoA, which is control‐
led by binding with 14-3-3, inhibit the formation of actin stress fibers and ultimately in‐
hibit  cell  migration.  Loss  of  expression  of  Kank-family  proteins  may  enhance  cell
migration in renal cell carcinoma. Since enhancement of cell migration is related to meta‐
stasis, Kank-family proteins might be related to the malignancy of renal cell carcinoma.
According to studies to date, the Kank1 protein may act as a tumor suppressor through
inhibition of cell migration and cell cycle. These functions are facilitated by several proteins
interacting with Kank1, including 14-3-3, IRSp53, Kif21a and Daam1. Further studies of the
interactions of these proteins will help us to understand clearly the role of Kank family proteins
in tumorigenesis.
3.4. Clinical study of Kank1 gene in renal cancer patients
3.4.1. Genetic and clinical characteristics of renal tumors
Kidney cancer accounts for about 4% of adult cancers, with an estimated 64,770 new cases
annually in the US (Siegel et al., 2012). Of kidney cancers, 92% are pathologically diagnosed
as RCC. This “RCC” has interesting and unique characteristics when investigated from a
clinical view point. Although 95% of patients with T1-T2 RCC survived 5 to 10 years, among
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those with metastatic disease the 5 year survival rate was 26% (DeCastro and McKiernan,
2008). Renal cancer is resistant to conventional chemotherapeutic agents and also to radiation
therapy. Many cancer-related genes have been found in renal cancer, including a multi-drug
resistance gene (Walsh et al., 2009), anti-apoptotic genes (Bilim et al., 2009), and radiation
resistant components (Kransny et al., 2010). The most characteristic genomic structure in renal
cancer is the VHL-related hypoxia-inducible factor gene and its cascades shown in hereditary
RCC and sporadic RCC cases (Linehan et al., 2011). The down-regulation in expression of
Kank1, our main theme, was also found from the study of renal cancer and normal renal tubular
cells (Sarkar et al., 2002), as we mentioned in other sections. The current WHO classification
of RCC in 2004 (Deng and Melamed, 2012) follows the earlier Heidelberg and Rochester
classifications, recognizing the heterogeneity of RCC, and describes distinct types of RCC with
unique morphologic and genetic characteristics. The most popular histological type, clear cell
RCC, accounts for 80 % of all RCC cases. Compared with clear cell RCC, papillary RCC (10%)
and chromophobe RCC (5%) are more benign. Collecting duct (bellini) (1%) type or other rare
sarcomatous types of RCCs are more aggressive (Deng and Melamed, 2012). However, once
metastasis occurs, papillary and choromophobe RCCs are more resistant to immunological
and new molecular targeting agents than clear cell RCC (Chowdhury et al., 2011). These clinical
features characterize the complexity of the clinical categorization of RCC.
Kank1  was found by a genome subtraction method among the genes at 9p24 susceptible
to  RCC  (Sarkar  et  al.,  2002).  A  devoted  study  revealed  that  Kank1  belongs  to  a  four-
member family, has splice variants, and plays a role in cell migration, intracellular trans‐
port  and  cell  division,  suggesting  that  Kank1  has  a  kind  of  tumor  suppressor  function
(Kakinuma et al., 2009). In this section, the expression of the Kank1 protein in renal can‐
cer specimens resected from RCC patients is indicated using immunohistochemical meth‐
ods,  and  the  relationship  between  the  expression  and  tumor  pathology,  patient  status,
and clinical outcomes is examined.
3.4.2. Expression of Kank1 protein in renal cancer and autologous normal kidney
1. Expression of Kank1 in RCC
We tried to find a RCC-related gene at 9p24, which lead to the discovery of Kank1. Of nine
ESTs analyzed in the 9p24 region, only three (WI-17492, WI-12779 and WI-19184) were
expressed in the kidney. The Kank1 gene was associated with WI-12779. This Kank1-associated
EST lost its expression in six out of eight cancer cases. Kank1 expression was examined in 5
matched normal kidney and cancer pairs by Western blotting using an anti-Kank1 antibody,
which was obtained as mentioned below. Reduced or loss of Kank1 expression in cancer was
observed in all 5 cases.
2. Immunohistochemical study of Kank1 expression in RCC and the relationship between its
expression and clinical-pathological outcomes
One hundred and five formalin-fixed paraffin-embedded slides including normal renal
tubular cells and RCC were subjected to immunohistological staining for Kank1 with a
monoclonal antibody. An anti-Kank1 (total Kank1) antibody was generated by a previously
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reported method (Roy et al., 2005). In brief, amino acids 406 to 580 of the Kank1 protein were
fused in-frame with the glutathione S-transferase gene in the vector pGEX. After induction of
the fusion protein in E. coli, it was purified and used to immunize mice. A mouse hybridoma
cell producing an anti-Kank1 antibody was selected and amplified for further use.
The histological subtypes of RCC analyzed here were as follows; 92 clear cell RCCs, 11 papillary
RCCs, 5 chromophobe RCCs and 7 other histological types. We compared all histological
subtypes with clear cell RCC. The evaluation of positivity of staining was done by two
independent examiners, who decided that the sample was positive when more than 30 % of
cells were stained with the antibody, weakly positive (±) when 5 to 30 % cells were stained,
and negative when less than 5 % cells were stained. The 2004 WHO histological classification
(Eble et al., 2004), 2002 TNM classification (Edge et al., 2010) and Fuhrman nuclear grade
(Fuhrman et al., 1982) were used in this study. Kaplan-Meyer cause-specific survival was
determined and statistical difference in positivity was evaluated by the Kluskal-Wallis test
using Stat View™ software following the instructions.
Representative examples of positive and negative staining for the Kank1 protein in clear cell
RCC and positive staining in normal renal tubular cells are indicated in Fig. 4. Normal renal
tubules usually expressed Kank1. Of 92 clear cell RCCs, Kank1 was positive in 47 cases (52%).
Kank1 was weakly positive (less than 30% of cells) in 14 cases (15%). Kank1 was negative in
29 cases (33%). The results grouped by clinical outcome (clear cell RCC) and histology are
summarized in Table 2. There was no relation or special tendency between the staining results




Clear cell Alive without cancer 29 11 18
Alive with cancer 7 1 4
Dead 11 2 7
Others 16 alive, 7 dead 21 2 1
Table 2. Immunohistological staining of Kank1 antibody classified by clinical outcome (clear cell RCC) and histological
subtypes. Sums of the numbers of patients do not match all the evaluated numbers due to inavailabilty of follow-up
to judge the clinical outcome.
There were no differences in the survival curves for clear cell RCC among the groups (Fig. 5).
However, when the positivity rate was evaluated among the groups divided by the Furman
nuclear grade, a highly malignant grade of clear cell RCC showed high Kank1 positivity (p <
0.05), while the others did not (Table 3). In clear cell RCC, 42% of grade 1 tumors were Kank1
negative, while 80% of grade 3 tumors were Kank1 positive. In other histological types, there
was no apparent difference among nuclear grades (most of them showed Kank1). When sub-
divided by pathological T stages, higher T stages of clear cell RCC showed a tendency to
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express Kank1 (p = 0.07) (Table 4). Other factors such as patient’s age, gender and the size of
the tumor (largest diameter) had no relation to the expression of Kank1 in clear cell and other
RCCs (data not shown).
Figure 4. Immunohistochemical analysis of Kank1 protein in clear cell RCC. There was a case of positive staining of
Kank1 protein in both normal renal tubular cells (upper left) and clear cell RCC (lower left), while another case indi‐
cates negative staining of Kank1 in clear cell RCC (lower right) while it was positive in the normal renal cells (upper
right) (reduced from 40× images).
Figure 5. Kaplan-meyer’s overall survival curve of RCC patients classified by Kank1 positivity (○ psitive; △ weakly posi‐
tive; □ negative). None of these survival curves showed statistical differences.
Renal Tumor18
Kank1
(+) (±) ( - )
Clear cell RCC grade 1 9 6 11
grade 2 31 6 19
grade 3 8 2 0
Others grade 1 5 0 0
grade 2 12 1 1
grade 3 5 1 0
Table 3. Results of Kank1 staining classified by histological grade.
Kank1
(+) (±) ( - )
Clear cell RCC pT1 27 10 17
pT2 5 2 8
pT3 14 2 4
pT4 2 0 0
Others pT1 11 1 1
pT2 5 0 0
pT3 5 0 0
pT4 1 1 0
Table 4. Results of Kank1 staining classified by pathological stage.
3.4.3. Meaning of Kank1 expression and clinical outcome
Many RCC cells showed inactivation of the Kank1 gene as shown here. This inactivation
presumably occurs at the early stage of carcinogenesis in normal renal tubular cells. Because
hemizygous methylation of Kank1 was observed in many cancer cells (Sarkar et al., 2002),
inactivation of Kank1 could be caused in both alleles by an epigenetic modification such as
methylation, rather than by mutations.
Concerning the genetic abnormality of RCC, mutations in the VHL gene are most prevalent
especially in clear cell RCC (Arai and Kanai, 2011). While VHL mutations can be found quite
often in sporadic clear cell RCC, they are not significant in other RCC histological subtypes or
benign oncocytoma. VHL mutations affect the activation of hypoxia-inducible factors, and
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investigation of this pathway will contribute to a new molecular targeting therapy for RCC
(Suwaki et al., 2011). The difference in VHL mutations among the RCC histological subtypes
suggests a difference in carcinogenesis for each histological subtype, though the origin of the
cancer is always a renal tubular cell.
Given that the alteration of Kank1 expression occurred at the early stage of carcinogenesis, our
findings that Kank1 expression differed among the histological subtypes of RCC might reflect
a difference in cancer development (Kim et al., 2005). In clear cell RCC, the loss of Kank1
expression occurred at a high rate in the lower grade tumors, and the expression was reoc‐
curred as the malignant grade increased. Although the reason for this is not clear, it is
presumed that epigenetic modifications such as methylation might have been removed when
the malignant grade increased, and consequently, the expression reoccurred (Kisseljova and
Kisseljov, 2005). There was no difference in Kank1 expression between the samples obtained
from the groups of patients who survived or not (Table 2). This may reflect the fact that
histological grade does not necessarily contribute to clinical outcome, but clinical stage (i.e.
the presence of metastasis) is more crucial to obtaining a good prognosis (RCC patients
diagnosed at the early stage have more than a 90% five year survival rate) (Lane and Kattan,
2008). The discordance of T stage (tumor size) and the malignant grade on Kank1 expression
could also be supposed for the same reason. A similar result was found for the expression of
CDKN2A encoding a growth suppressor protein, which is located at 9p21 and close to Kank1
(9p24) (unpublished data). Although the loss of Kank1 expression resulted in increased
proliferation and poor differentiation in in vitro study (Sarkar et al., 2002), our results about
the in vivo expression of Kank1 in clinical cases proved that reduced expression does not
necessarily reflect a high grade malignancy or poor clinical outcome. These contradictory
experimental and clinical results are very interesting, because they suggest that malignant
transformation of a normal renal tubular cell has many genetic alterations and clinical outcome
is contributed to by many factors in RCC.
4. Prospect of using Kank family genes in genetic diagnosis and gene
therapy for renal tumors
4.1. Future diagnostics for RCC
The lack of clinical impact of the current diagnostic markers for RCC apparently requires
progress in methodology, biology and pathology (Stewart et al., 2011). The progress in
methodology needs the quality of the methods to satisfy the specificity, stability and biological
relevance of the markers for diagnosis. For this, sufficient numbers, tens to thousands, of
markers would be needed and such markers could be obtained only through cellular signaling
analyses. There are quite a number of potential protein and genetic markers for diagnosis and
therapeutic targets of RCC based on the information of signal transduction (see Section 2), and
more information would be added in the future. While sampling is easier for DNA and RNA-
based assays, protein assays such as immunohistochemistry and more advanced mass-
spectrometry techniques have problems of contamination and degradation/modification at
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sampling and processing. In immunohistochemisty, protein cross-linking at the preparation
steps disturbs antibody binding. Sampling of homogenously expressed proteins is crucial for
the stability of assays, but would not be possible for most sampling cases as the tissue itself is
not homogenous. However, diagnosis even for such cases could be possible with markers
sufficiently distinguishing heterogenously expressed proteins in different parts of the diseased
tissue. In all cases, a statistical significance analysis should be included as a standard evaluation
step for quality control of multi-marker systems such as DNA microarrays (Shi et al., 2010).
Biologically relevant markers will be made available in the future based on the analysis of
signal transduction, because, as shown in Fig. 1 (Section 2), there are a number of markers
available even within a single signaling pathway and there are sufficient numbers of different
pathways affected by the disease, which will contribute to the stability of assays. As discussed,
the VHL and mTOR pathways have drawn much attentions to prognosis/diagnosis and
therapeutic targets for RCC, but there are more pathways such as the Myc and FLCN pathways
and pathways related to VEGF, PDGF and TGFα, and some are specific to subtypes of RCC
(Linehan et al., 2010; Allory et al., 2011).
Meanwhile, pathologically relevant markers will also be made available in the future, although
the situation is different from other technologies due to the technical limit in the number of
markers to examine simultaneously.
4.2. A new fluorescence-based immunohistochemical technique
One obstacle  to  improving immunohistochemistry  is  the  availability  of  markers.  Immu‐
nostaining is a relatively simple technique and thus can be used in unequipped laborato‐
ries  and  hospitals,  because  the  preparation,  storage  and  handling  of  samples  are
relatively  simple.  However,  ordinary immunostaining is  based on single-dye (or  single-
marker)  colorimetric  techniques  such as  the  alkaline  phosphatase-based method.  This  is
because  of  a  lack  of  multi-dye  (or  multi-marker)  colorimetric  techniques  due  to  expen‐
sive  devices  and,  especially,  inavailability  of  stable  fluorescent  dyes.  Fluorescent  dyes
have been used in many technologies although this has not happened yet in immunohis‐
tochemistry  because  of  the  lack  of  their  sufficient  stability.  Stable  fluorescent  dyes  are
thus needed for progress in immunohistochemistry.
We reported applications of a new fluorescent dye, Fluolid, for DNA microarray assays and
immunohistochemistry (Zhu et al., 2011). Fluolid dyes, including Fluolid-Orange, show
stability against heat and excess light compared with other dyes (Fig. 6) and thus can be stored
for more than a year without losing fluorescence (data not shown). So, multi-color immuno‐
histochemistry with stable fluorescent dyes will change the pathological diagnostics in several
ways: long-term storage of stained sections, simultaneous multi-marker detection and
handling of fluorescently stained sections. Heat and light stable fluorescent dyes will enable
us to store fluorescently stained sections at room temperature for a long time, which will be
important for follow-up studies by microdissection of specific regions.
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Figure 6. Stability of fluorescently labeled IgG. (A) Photostability of Fluolid-Orange- or Cy3-labeled IgG under irradia‐
tion for up to 150 sec with a laser beam at 488 nm. (B) Heat stability. Fluolid-Orange- or Cy3-labeled IgG was left in an
environment of 100ºC and fluorescence was measured every 30 min. For details, see Zhu et al. (2011).
4.3. Future therapeutics
As discussed in Section 4.1, future diagnosis will be based on sufficient numbers of protein
markers possibly obtained from signal transduction pathways, which will give a statistically
significant decision even for cases where no decisive markers, such as disease-causing
mutations or constitutive active proteins, are available. In the case of future therapeutics,
multiple targets will also be considered to be an effective strategy. Signal transduction-based
targeted therapeutics have already been developed for some diseases and drugs such as
imatinib or Gleevec/Glivec, a small molecule inhibitor against activated tyrosine kinase activity
by the Bcr-Abl fusion gene used for the treatment of chronic myelogenous leukemia, are
available (Radford, 2002). Other monoclonal antibody-based drugs such as trastuzumab or
Herceptin, which blocks a growth factor receptor HER2/neu (c-erbB-2) to treat breast cancer,
and panitumumab or Vectibix, which blocks HER1 to treat colorectal cancer, have been
developed based on signal-transduction. Although these drugs are effective, continuous use
will sometimes generate drug-resistant cancer (Schenone et al., 2011). So, treatment with
multiple targeting drugs will be important in future therapeutics and the same is true for the
matched diagnostics about multiple targets.
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